99 results about "Escherichia albertii" patented technology

The invention discloses a strain capable of producing succinic acid, a method for producing the succinic acid and an application thereof. The strain is named as Escherichichia coil BER208 with the collection number of CCTCCNO: M2012351. The strain grows quickly with glucose serving as the single carbon source in a fermentation medium under the anaerobic condition and is capable of highly producing the succinic acid. The optical density (OD) 6000 reaches 6.87 and the yield of the succinic acid reaches 10.5g / L after fermentation for 48 hours, and compared with an original strain, the yield of the succinic acid is improved by more than two times.

The invention relates to trosine phenol lyase engineering bacteria as well as a construction method thereof and application thereof. A tyrosine phenol lyase gene is constructed to express plasmids; chaperonin is introduced to express the plasmids to obtain the trosine phenol lyase engineering bacteria which are identified as escherichia coli FPLF8 (Escherichia coli HPLF8) preserved in China Center for Type Culture Collection on February 19, 2016, with a preservation number being CCTCCNO:M 2016065. The engineering bacteria can be synthesized into levodopa by fermentation and conversion, and are efficiently expressed; the expressed product is stable and high in activity, and can be synthesized into levodopa by conversion in the presence of related substrates; and the process is simple, the cost is low, the yield is high, emission of three wastes is a little, and the application value for industrial production is achieved.

The present invention provides a Bifidobacterium lactis capable of regulating gastrointestinal florae and application of the Bifidobacterium lactis BL-99, and belongs to the technical field of microorganisms. The Bifidobacterium lactis has gastric acid resistance, the survival rate of viable bacteria is 62% or above after the Bifidobacterium lactis BL-99 is treated for 30 min in a pH 2.5 gastric acid solution, and the survival rate of viable bacteria is 61% or above after the Bifidobacterium lactis BL-99 is treated for 2 h. The bacterium can significantly promote the growth of bifidobacteria and lactic acid bacteria, and can inhibit desulphovibrio / enterobacter in intestinal tracts, especially curatively inhibit helicobacter pylori and / or Escherichia-Shigella, can be used to prepare food, medicines and feed with gastrointestinal tract flora regulation effects, and has wide application prospects.

The invention relates to a genetic engineered bacterium which contains a recombinant plasmid pET28a-GMAS, is 6585 bp in a plasmid size, is 1308 bp in a fragment size of a GMAS, is named as Escherichia coli and has a kanapenecilin resistance. Genes of the [gamma]-glutamylmethylamine synthetase are inducibly expressed by isopropylsulpho-[beta]-D-galactoside. The genetic engineered bacterium has a capability of biologically synthesizing theanine. By means of glutamic acid and ethylamine as substrates, a method in the invention is simple in operation method, is convenient to control in production, is high in conversion and production efficiency of the theanine and has an excellent industrial application prospect.

Cis,cis-muconic acid is an important chemical organic acid, has a wide range of application and can be used as a precursor of adipic acid. The cis,cis-muconic acid can be used for producing polymers including nylon 66 and the like after being converted into adipic acid through hydrogenation. The invention provides a recombinant escherichia coli TIB-LEc340 CGMCC No 6435 for producing cis,cis-muconic acid, wherein the recombinant escherichia coli is established by the steps of combining 3-dehydrogenated shikimic acid dehydrase which comes from different microbes and is optimized by codons, protocatechuic acid decarboxylase, catechol 1,2-dioxidase and artificially designed constitutive promoters and terminators into a heterologous expression module, and then introducing the heterologous expression module into shikimic acid dehydrogenase mutated escherichia coli. The escherichia coli TIB-LEc340 CGMCC No 6435 is fermented for 16-120 hours at 30-40 DEG C to obtain fermentation liquor, and the maximum content of cis,cis-muconic acid in the fermentation liquor can reach 52g / L, so that the escherichia coli has a wide application prospect.

The invention provides a plant bacteriostatic composition and application thereof in a liquid detergent. The composition is compounded by perillae extracts, flos lonicerae extracts and murraya paniculata extracts. The composition has a good bacteriostatic effect, in particular, has a synergistic effect in the aspect of suppressing staphylococcus aureus, Escherichia coli, pseudomonas aeruginosa, aspergillus niger and candida albicans. The bacteriostatic composition can be applied to the liquid detergent to realize a bacteriostatic effect, so that the additive amount of chemosynthetic preservatives is reduced, and the expiration date of products is ensured to be unchanged.

The invention belongs to the technical field of bioengineering, and relates to a genetic engineering bacterium for producing succinic acid and a method for producing the succinic acid by fermentation, in particular to a recombinant strain which is grown by utilizing xylose efficiently and is used for producing the succinic acid and a method for producing the succinic acid by utilizing the fermentation of the strain. The genetic engineering strain for producing the succinic acid belongs to the class of Escherichia coli BA204, and the conservation register number is CCTCC No:M2011207. A construction process comprises the steps of: inactivating or removing phosphoenolpyruvate carboxylase, and over-expressing phosphoenolpyruvate carboxylation kinase, so that the recombinant Escherichia coli can be grown by utilizing xylose metabolism to improve the synthetic efficiency of the succinic acid is improved substantially. In the fermentation method, a two-stage fermentation mode is adopted, wherein in an aerobic stage, biomass is improved; and in an anaerobic stage, acid is produced by the fermentation.

The invention relates to the construction and expression of a strain by virtue of a genetic engineering method, discloses (escherichia coli) BTE-9 which was collected in the CGMCC (China General Microbiological Culture Collection Center) on April 16, 2012 with the collection number of CGMCC NO. 6014 and provides a method for efficiently secreting and expressing the human epidermal growth factor by using the (escherichia coli) BTE-9. During fermenting and expressing, no inducer is used, so that the change of the physiological state and the loss of plasmids due to an adopted inducer are avoided, the production cost is reduced, and the pollution of the toxic inducer to a target product is avoided, and high expression quantity is achieved.

The invention provides a recomposed large intestine Escherichia coli expressing adenosine methionine synthetase with CGMCC No. 2299 and the composition method of the recomposed large intestine Escherichia coli. The invention further provides a recomposed expression carrier pMETK of adenosine methionine synthetase. In the recomposed large intestine Escherichia coli expressing adenosine methionine synthetase with CGMCC No. 2299, the expression quantity of the adenosine methionine synthetase accounts for 31.36 percent of soluble albumen of the strain, the activity of the adenosine methionine synthetase expressed is as high as 7.38U / ml, far higher than that of wild type strains.

The invention relates to growth-inhibitory composition against pathogenic bacteria of meat based food stuff comprising IgY. The IgY is a specific immunoglobulin derived from yolk of egg. 12 representative bacteria and other microbes deteriorating quality of process meat products that the IgY of the invention targets include Aeromonas hydrophila, Bacillus cereus, which comprises Aeromonas hydrophil, Bacillus cereus, Camphlobacter jejuni, Clotridium perfringens, 0157:H7 (Escherichia col, 0157:H7), Lactobacillus, Listeria monocytogens, Saccharomyces cerevisiae, Salmonella enteritidis, Salmonella typhimurium, Staphylococcus aureus, Staphylococcus epidermidis. The 12 representative bacteria antigen forms are respectively injected the interior of chicks to obtain the IgY of the 12 antigens.

The invention relates to Escherichia coli JLTrp and application thereof to the fermentation production of L-tryptophan. The Escherichia coli JLTrp has a culture collection number of CGMCC NO. 7.217. The application of the Escherichia coli JLTrp to the fermentation production of the L-tryptophan comprises the following steps: performing inoculation with mature cultures in a fermentation tank, at a temperature of 34-36 DEG C, controlling pH (potential of Hydrogen) in a staged manner by adopting liquid ammonia replenishment, controlling dissolved oxygen in the staged manner, controlling the pressure to be 0.03-0.08MPa and the air volume to be 0.3-2.0VVM, controlling residual sugar to be 0.01-0.5% in a process, and cultivating and preparing L-tryptophan. A bacterial strain of the Escherichia coli JLTrp greatly improves the stability of the cultures, and reduces the generation, which is caused by insufficient conditions, of an organic acid, so that the vitality of the cultures is improved, cultivation conditions are gradually lowered, and energy consumption is greatly reduced. Escherichia coli JLTrp provided by the invention can be used for the fermentation production of L-tryptophan, is relatively greatly improved in both yield and percent conversion, and has obvious progress.

The invention provides a recombinant microorganism for producing cytosine. The recombinant microorganism is classified and named as Escherichia coli., the strain is preserved in China General Microbiological Culture Collection Center on May 08, 2019, the address is Institute of Microbiology, Chinese Academy of Sciences, No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the postcodeis 100101; and the preservation number of the strain is CGMCC No. 17730. The recombinant microorganism for producing the cytosine is fermented to obtain the cytosine; or nucleoside hydrolase is addedinto the cytidine fermentation liquor or the solution containing cytidine to produce cytosine.

The invention discloses a grass carp haemorrhagic virus resisting engineered protein TAT (Trans-activating Transcriptional Activator)-VP7-TAT as well as a preparation method and application thereof. The amino acid sequence of the TAT-VP7-TAT protein is shown as SEQ ID NO:2, and a corresponding nucleotide sequence is shown as SEQ ID NO:1. By using Eschierichia coli BL21(DE3) / pET-32a-TAT-VP7-TAT to perform inducible expression for 4 to 5 hours, a TAT-VP7-TAT fusion protein can be efficiently expressed; the N end and the C end of the protein are respectively provided with protein transduction domain polypeptide TAT. The genetic engineering fusion protein provided by the invention can be used for preventing grass carp haemorrhagic virus diseases. The fusion protein has the advantages of high expression, easiness for industrial production, low cost and good safety; grass carp orally takes the fusion protein, so that better immune protection is realized.